Business
PRTC Gets $11.4M Grant for Ph2 of LYT-300 in FXTAS
PRTC Gets $11.4M Grant for Ph2 of LYT-300 in FXTAS.
About this update from Puretech Health Plc
[{"type":"text","content":"\n\n1 August 2023\nPureTech Health plc\n \nPureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome\n \nPlanning underway for Phase 2 trial of LYT-300 in Fragile X-associated Tremor/Ataxia Syndrome\n \nLYT-300 is also being evaluated in a Phase 2a trial for anxiety disorders, and a Phase 2a in patients with postpartum depression is planned to initiate in second half of 2023\n \nLYT-300, LYT-310 and additional preclinical programs for CNS indications have been produced from PureTech's GlyphTM technology platform for enhancing oral bioavailability\n \nPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the company has been awarded up to $11.4 million from the U.S. Department of Defense (DoD) to advance its therapeutic candidate, LYT-300 (oral allopregnanolone), for the treatment of Fragile X-associated Tremor Ataxia Syndrome (FXTAS). The funds will support a Phase 2 trial of LYT-300 in collaboration with the University of California, Davis (UC Davis).\n \nLYT-300, an oral prodrug of allopregnanolone, is PureTech's wholly-owned therapeutic candidate for the potential treatment of anxiety disorders, postpartum depression, FXTAS and other neurological and neuropsychiatric indications. LYT-300 was developed using PureTech's GlyphTM platform, which harnesses the body's natural lipid absorption and transport process to enable the oral administration of certain therapeutics that otherwise cannot be administered orally.\n \nFXTAS, which was discovered by Dr. Randi Hagerman and her colleagues at the University of California, Davis, is a devastating neurological condition that is closely related to, but distinct from, Fragile X syndrome (FXS). Both conditions are the result of repeated elements in the Fragile X Messenger Ribonucleoprotein Gene 1 (FMR1) gene. While FXS is associated with intellectual disability and autism, FXTAS leads to neurodegeneration in otherwise normally developed, aging individuals who carry a premutation of the FMR1 gene.\n \n\"FXTAS is a devastating, late-onset neurodegenerative condition characterized by cognitive d...